190 related articles for article (PubMed ID: 28851197)
1. [The influence factors of quality-of-life in patients with thyroid-associated ophthalmopathy].
Shen L; Zhu H; Li XX; Liu DD; Chen XY; Liu H
Zhonghua Yan Ke Za Zhi; 2017 Aug; 53(8):575-582. PubMed ID: 28851197
[No Abstract] [Full Text] [Related]
2. [Evaluation of quality of life in patients with Graves orbitopathy and its influencing factors].
Weng CY; Li ZF; Hu SD; Luo YS; Feng XT; Zhong Q; Zhang Q; Shen J
Zhonghua Nei Ke Za Zhi; 2019 Aug; 58(8):577-583. PubMed ID: 31365979
[No Abstract] [Full Text] [Related]
3. [Triamcinolone acetonide deep fornix injection for the treatment of upper eyelid retraction in patients with thyroid-associated ophthalmopathy].
Luo LH; Gao LX; Wang W; Miao H; Ma XM; Li DM
Zhonghua Yan Ke Za Zhi; 2020 Jul; 56(7):524-529. PubMed ID: 32842335
[No Abstract] [Full Text] [Related]
4. Strabismus surgery for improving the quality of life of strabismus patients with thyroid-associated ophthalmopathy.
Huang Y; Li K; Yan Y; He J; Chen J
Medicine (Baltimore); 2023 Sep; 102(35):e34778. PubMed ID: 37657062
[TBL] [Abstract][Full Text] [Related]
5. Prevalence, Phenotype, and Psychosocial Well-Being in Euthyroid/Hypothyroid Thyroid-Associated Orbitopathy.
Ponto KA; Binder H; Diana T; Matheis N; Otto AF; Pitz S; Pfeiffer N; Kahaly GJ
Thyroid; 2015 Aug; 25(8):942-8. PubMed ID: 26244413
[TBL] [Abstract][Full Text] [Related]
6. Assessing quality of life in Taiwanese patients with Graves' ophthalmopathy.
Lin IC; Lee CC; Liao SL
J Formos Med Assoc; 2015 Nov; 114(11):1047-54. PubMed ID: 24434244
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the National Eye Institute visual function questionnaire in Graves' ophthalmopathy.
Bradley EA; Sloan JA; Novotny PJ; Garrity JA; Woog JJ; West SK
Ophthalmology; 2006 Aug; 113(8):1450-4. PubMed ID: 16769116
[TBL] [Abstract][Full Text] [Related]
8. Thyroid-associated ophthalmopathy; quality of life follow-up of patients randomized to treatment with antithyroid drugs or radioiodine.
Abraham-Nordling M; Wallin G; Träisk F; Berg G; Calissendorff J; Hallengren B; Hedner P; Lantz M; Nyström E; Asman P; Lundell G; Törring O;
Eur J Endocrinol; 2010 Oct; 163(4):651-7. PubMed ID: 20660002
[TBL] [Abstract][Full Text] [Related]
9. [A study on observing the central macular choroidal thickness of thyroid-associated ophthalmopathy patients with spectral-domain optical coherence tomography].
Zhu Y; Song Y; Cai Q; Zhou Y; Li JJ
Zhonghua Yan Ke Za Zhi; 2018 Sep; 54(9):688-693. PubMed ID: 30220185
[No Abstract] [Full Text] [Related]
10. Therapeutic outcomes of mycophenolate mofetil and glucocorticoid in thyroid-associated ophthalmopathy patients.
Li LF; Xue JL; Guan L; Su FF; Wang H; Zhang DF
Front Endocrinol (Lausanne); 2023; 14():1140196. PubMed ID: 37025403
[TBL] [Abstract][Full Text] [Related]
11. [The level of cotinine - marker of tobacco smoking, in patients with hyperthyroidism].
Czarnywojtek A; Zgorzalewicz-Stachowiak M; Florek E; Piekoszewski W; Warmuz-Stangierska I; Kulińska-Niedziela I; Komar-Rychlicka K; Sowiński J
Endokrynol Pol; 2006; 57(6):612-8. PubMed ID: 17253434
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of quality of life in patients with Graves´ ophthalmopathy, before and after orbital decompression.
Iacobæus L; Sahlin S
Orbit; 2016 Jun; 35(3):121-5. PubMed ID: 27159575
[TBL] [Abstract][Full Text] [Related]
13. Quality of life in Graves' ophthalmopathy.
Wiersinga WM
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):359-70. PubMed ID: 22632371
[TBL] [Abstract][Full Text] [Related]
14. Prevalence, risk factors, and clinical features of thyroid-associated ophthalmopathy in multiethnic Malaysian patients with Graves' disease.
Lim SL; Lim AK; Mumtaz M; Hussein E; Wan Bebakar WM; Khir AS
Thyroid; 2008 Dec; 18(12):1297-301. PubMed ID: 19012471
[TBL] [Abstract][Full Text] [Related]
15. [The value of DCE-MRI in assessing the course of thyroid associated ophthalmopathy].
Wu T; Tang DR; Wang F; Xia S; Sun FY
Zhonghua Yan Ke Za Zhi; 2017 Jun; 53(6):430-435. PubMed ID: 28606264
[No Abstract] [Full Text] [Related]
16. Which factors are associated with quality of life in patients with Graves' orbitopathy presenting for orbital decompression surgery?
Wickwar S; McBain HB; Ezra DG; Hirani SP; Rose GE; Newman SP
Eye (Lond); 2015 Jul; 29(7):951-7. PubMed ID: 25998940
[TBL] [Abstract][Full Text] [Related]
17. Assessing Graves' ophthalmopathy-specific quality of life in Korean patients.
Choi YJ; Lim HT; Lee SJ; Lee SY; Yoon JS
Eye (Lond); 2012 Apr; 26(4):544-51. PubMed ID: 22241019
[TBL] [Abstract][Full Text] [Related]
18. Related quality of life questionnaire specific to dysthyroid ophthalmopathy evaluated in a population of patients with Graves' disease.
Delfino LC; Zunino A; Sapia V; Croome MDCS; Ilera V; Gauna AT
Arch Endocrinol Metab; 2017; 61(4):374-381. PubMed ID: 28225858
[TBL] [Abstract][Full Text] [Related]
19. Serum concentrations of adiponectin and resistin in hyperthyroid Graves' disease patients.
Sieminska L; Niedziolka D; Pillich A; Kos-Kudla B; Marek B; Nowak M; Borgiel-Marek H
J Endocrinol Invest; 2008 Sep; 31(9):745-9. PubMed ID: 18997483
[TBL] [Abstract][Full Text] [Related]
20. Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments.
Terwee CB; Dekker FW; Mourits MP; Gerding MN; Baldeschi L; Kalmann R; Prummel MF; Wiersinga WM
Clin Endocrinol (Oxf); 2001 Mar; 54(3):391-8. PubMed ID: 11298093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
